All catalysts expected in the coming days:
$ADXS Who cares or gives a .... where it closed at. The point is that 7 catalysts are expected in 2nd half of 2019. Get a clue people. You want the catalysts here they are:
1,) Updated survival data from phase 2 heavily pre-treated metastatic castration-resistant (meaning they don't respond to ADT anymore) prostate cancer patients lm treatment +Keytruda combination expected 2nd half of 2019
2,) Advaxis NEO in multiple solid tumor cancers immunogenicity and safety data expected 2nd half 2019
3.) Initiation of study Part B Advaxis NEO in multiple solid tumor cancers combining NEO + checkpoint inhibitor expected 2nd half of 2019
4,) Immunogenicity and safety data from ADXS-503 HOT in non-small cell lung cancer (Merck has biggest hold in NSCLC worth billions of dollars space) expected 2nd half of 2019
5,) Initiation of Part B ADXS-503 HOT in NSCLC study in combination with checkpoint inhibitor expected 2nd half of 2019
6,) IND submission ADXS-504 HOT Prostate cancer to begin study expected 2nd half of 2019
7,) Announcement of Investigator sponsored trial of ADXS-HPV in head and neck cancer to begin study expected 2nd half of 2019
2020 catalysts:
1.) IND Submission ADXS-506 HOT bladder cancer expected 1st half 2020
2,) Data unblinding of phase 3 halted study of AIM-2-CERV (if good could end up being partnered ) 1st half of 2020
Can you all stop the bearishness and bickering now? Thanks.
